{"type":"trials","record":{"id":33075,"source_id":"clinicaltrials-gov","external_id":"NCT03371134","title":"Role of HIF-1α in Skeletal Muscle Aging","brief_summary":"Deficits in skeletal muscle function exist during aging and muscular dystrophy, and suboptimal function has been related to factors such as atrophy, excessive inflammation and fibrosis. Sarcopenia is the age-related loss of skeletal muscle mass and function. It is now recognised as a major clinical problem for older people and research in the area is expanding exponentially. This interest stems from the fact that sarcopenia is both common and associated with serious health consequences in terms of frailty, disability, morbidity and mortality. The age-related loss of human skeletal muscle mass is due to a decrease in myofibre size and number with the loss of both fast and slow type myofibres, although the loss of fast myofibres tends to start earlier, at ∼70 years. Many factors influence the decrease in muscle mass. A significant contributor is an anabolic resistance of older skeletal muscle to protein nutrition as seen during immobilisation which can be ameliorated at least in part by resistance exercise and dietary supplementation. Other intensive areas of research are related to the loss of innervation and oxidative damage. Moreover, ineffective muscle regeneration underlies each condition and has been attributed to a deficit in myogenic potential of resident stem cells or satellite cells. It is now widely accepted that satellite cells, and generally adult stem cells, are normally quiescent and tend to reside in hypoxic areas of the tissue to preserve their undifferentiated state. To govern these processes, cells have developed a very complex machinery that is mainly regulated by a group of transcription factors known as hypoxia-inducible factors (HIFs). In particular, several observations support the idea that oxygen deprivation and HIF-1a may play a key role during ischemia to activate the regeneration process, which, after an initial hypoxic insult, needs to proceed under normoxia. On these bases, in this study we will investigate the role of HIF-1a in skeletal atrophy during aging.","overall_status":"Unknown","phases":[],"study_type":"OBSERVATIONAL","sponsor":"I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio","enrollment":16,"countries":[],"start_date":"2018-01-10","completion_date":"2020-07-26","last_update_date":"2017-12-14","source_url":"https://clinicaltrials.gov/study/NCT03371134","editorial_summary":"A registered study indexed because it matched monitored longevity research terms. Registry status: Unknown. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:20:06.962668+00:00","last_seen_at":"2026-09-25T06:15:20.281+00:00","metadata":{"sex":"ALL","acronym":"HIF","age_range":"18 Years to 90 Years","comparator":null,"organization":"I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio","interventions":["Harvesting of muscular biopsies"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Evaluation of HIF-1a expression levels in satellite cells isolated from sarcopenic and young — 1 year","Evaluation of sarcopenic profile in satellite cells harvested from old sarcopenic patients — 6 months","Correlation of HIF-1a levels with the degree of sarcopenia in the satellite cells of old sarcopenic patients — 1 year","Evaluation of differences in satellite cells number between young and old patients — 6 months","Evaluation of HIF-1a stabilization on satellite cells treated with PHDs inhibitors — 1 year","Evaluation of satellite cell proliferation in cells treated with PHDs inhibitors — 1 year","Evaluation of satellite cell differentiation in cells treated with PHDs inhibitors — 1 year"],"design_description":null,"source_has_results":false},"controlled_terms":["Sarcopenia","Harvesting of muscular biopsies"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":50,"publication_state":"published","match_explanation":"Title contains controlled term: muscle aging.","quality_checked_at":"2026-09-25T06:15:30.843286+00:00","duplicate_cluster_key":"id:nct03371134","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2018-01-10 to 2020-07-26","comparator":null,"confidence":"structured-source","population":"ALL · 18 Years to 90 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:15:20.402Z","intervention":["Harvesting of muscular biopsies"],"participants":16,"study_design":"OBSERVATIONAL","subject_scope":"Human clinical study registration","evidence_stage":"Phase not reported","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Evaluation of HIF-1a expression levels in satellite cells isolated from sarcopenic and young — 1 year","Evaluation of sarcopenic profile in satellite cells harvested from old sarcopenic patients — 6 months","Correlation of HIF-1a levels with the degree of sarcopenia in the satellite cells of old sarcopenic patients — 1 year","Evaluation of differences in satellite cells number between young and old patients — 6 months","Evaluation of HIF-1a stabilization on satellite cells treated with PHDs inhibitors — 1 year","Evaluation of satellite cell proliferation in cells treated with PHDs inhibitors — 1 year","Evaluation of satellite cell differentiation in cells treated with PHDs inhibitors — 1 year"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"sarcopenia","is_published":true,"match_reasons":["Title contains controlled term: muscle aging.","Abstract contains controlled term: sarcopenia.","Source terminology contains: sarcopenia.","Title supplies longevity context: aging.","Study type is explicitly identified as OBSERVATIONAL."],"matched_fields":["title","abstract","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Sarcopenia","slug":"sarcopenia"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/33075","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}